Wednesday, December 14, 2011

JOY Global Shares Hit hard by Mining Equipment Outlook

Joy Global shares were down 10.75% at 2PM. Joy global warns that their production growth could be moderate because of weaker demand for commodities. Joy Global predicts growth to be at a “more tempered pace”. They reported revenue that was slightly short of analyst expectations. Spot prices for coal, copper and iron ore are down from highs set earlier this year by as much as 20 percent, the company noted in the announcement of its earnings. JOY will now shift their focus on long term growth.


Market Vectors-Coal ETF (-.69, -2.06%) has seen a 12% decline in the last month. Market Vectors-Coal ETF (the Fund) seeks to replicate as closely as possible the price and yield return performance of the Stowe Coal Index (COAL or the Index) by investing in a portfolio of securities that generally replicates COAL. There is some fear that the ETF could fall just below its October low of $27.50. Joy Global currently makes up 11% of KOL’s weight.

-Jim

JOY Reports Sad Earning's

Joy Global released their annual report today, December 14, 2011. Despite positive words from CEO Mike Sutherlin, saying "Our fourth quarter was a good finish to an exceptional year,” the market interpreted the results in a much different manor. Missing their quarterly EPS $.06, a 3.3% miss, the stock opened down 4.84% and his since fallen further to an 11.85% loss for the day. The miss on EPS combined with a 2012 annual EPS target set by the company of anywhere between $7.00 and $7.40, a high range, especially considering the market is expecting 7.19, allowing for room for failure.

In the report itself, Joy Global stressed its increase in future bookings and a more forward approach discussing the future growth more than the current year’s success, or lack thereof. With the purchase of LeTourneau Mining, combined with the future bookings, does not rule out the possibility of a large comeback year, especially if Joy Global can hit the upper end of its projected EPS. The downsides continue with growth for mining in India and China not appearing as vibrant as once thought, with FactSet stating that the region will "grow at a more moderate rate in 2012." AS banks start to react to this news, favorability towards the stock is declining with JPMorgan lowering its price target for the company from $97 to $85, a 14% decrease. With so much growth of the company dependant on world macroeconomic success, JPMorgan felt that the company would continue its sluggish growth until we began to see more of an economic upturn.

- Matt Buechele

Monday, December 12, 2011

ECL Active in Acquisition Market

On Thursday, December 8, 2011 Ecolab Inc. announced the acquisition of the Brazilian pest control company InsetCenter, which has about $6 million in annual sales. Ecolab plans to merge InsetCenter into its existing pest elimination business in Brazil. The terms of the deal were not disclosed but Douglas M. Baker, Jr., Ecolab's Chairman and CEO commented on the announcement, saying, "This acquisition will substantially increase our Brazilian Pest Elimination service capacity and scale to our business, making us the leader in commercial pest elimination in Brazil”. Ecolab was up $0.03 (0.05%) at the close today after a late general market sell off.

It has been a very busy month for Ecolab with its acquisitions of Nalco, the world's leading water treatment and process improvement company and the Italian health care products maker Esoform and as of today, InsetCenter. I believe that the recent acquisitions coupled with its strong performance in recent months are a good indication of growth on a global scale.

-Drew Sweeney, Junior Analyst

Wednesday, December 7, 2011

Halliburton had sharp decline after BP's filed an accusation

Tuesday (12/6) morning, Halliburton Co. opened at $36.57(-1.22%) after BP filed an accusation Monday (12/5) evening, of “intentionally destroying evidence” relating to the Deepwater Horizon disaster in the Gulf of Mexico last year, the world’s largest accidental offshore oil spill.

In New Orleans, the trial for damages arising from the spill, BP alleged that Halliburton had destroyed test results and computer analysis “because it wanted to eliminate any risk that this evidence would be used against it at trial”. The first trial over the Deepwater Horizon disaster is scheduled to start Feb. 27 in New Orleans.

Halliburton ranged from day’s low at $34.86 to  high at $36.73. It closed at $35.57 (-3.92%)

---Richard Yun-----

Tuesday, November 29, 2011

JOY Global 'to the World'; Joy Global up 7% on the day

On November 29, 2011, Joy Global saw an incredible one day rise of $5.94 per share, to settle at a price of 84.72. This seven and a half percent rise was mostly due to the fact that we are in the midst of extremely volatile times for financial markets. Opening the day with the two positive stories, the legendary sales on Black Friday combined with positive news regarding negotiations concerning the debt crisis in Europe, was able to give way for a two a half percent rise in the Dow Jones Industrial.


The reasons pertaining to Joy’s particularly favorable numbers could be the result of a multitude of factors. Firstly, being one of the more risky companies within its sub-industry, Joy had dropped over 8 percent from November 18-25 on speculation of possible takeovers and moves into China by one of their main competitors, Caterpillar, Joy could have been undervalued coming into the day, and saw over exaggerated gains. The only official news released by the company for the day was its announcement that it would be giving out a dividend of $0.175 for the quarter, which did seem to be encountered as a surprise by the market. So with limited aspects for growth on the day, I do not think we can see this rise in the company’s market share as a significant source of growth, but rather a move with the market that could perhaps do the opposite with any negative news in the upcoming days.

-Matthew Buechele

Monday, November 21, 2011

Illinois Tool Works Sale

We made the decision to sell our position in Illinois Tool Works, Inc. Based on the fact that we hit our price target and believe our thesis upon which we bought into ITW has been fulfilled. Also, we are bearish on ITW going forward due to their high exposure to Europe, specifically Italy. We will be recognizing a 30% plus gain.

-John Astarita

Monday, November 14, 2011

Allscripts: Profit Rises and Beats Estimates

Allscripts beat analysts’ Q3 estimates and saw a significant jump in year-over-year growth, accelerating revenue, and net income. For the Q3, Allscripts Healthcare Solutions (MDRX) recorded revenue of $371.4 million, up 13% from last year’s Q3, with about 65% of this revenue noted to be reoccurring. System sales revenue grew 15% year-over-year, reflecting revenue sales from new client sales in the quarter. Professional services revenue increased 22% year-over-year and attributed to the decline in gross margin. Maintenance revenue climbed 9%, due to robust go-live activity in both their acute and ambulatory segments. Transaction processing and other revenue grew approximately 11%. Gross margin was recorded at 45.7% compared to 48.9% in the prior year, due to a broader mix of professional services and higher number of third-party system sales in the third quarter of 2011.

Operating profit margin was 20.3%. Furthermore, net income for Q3 totaled $47.3 million, a 28% increase over the $36.8 million over the last year. Diluted adjusted earnings per share were $0.25, a 32% increase over last year and beat analyst’s estimates of $0.23 earnings per share. For the third quarter of 2011, cash flow from operations totaled $42.2 million. They also eliminated $45.5 million in borrowings, the largest quarterly reduction to date. Allscripts recorded $267 million in bookings, representing a 34% growth year-over-year. It should be noted that these numbers have been adjusted and are non-GAAP, essentially excluding the costs related to its $1.3 billion buyout of Eclipsys last year.

Allscripts sees regulatory issues as an opportunity for growth in the future. The revisions in the healthcare system and adoption of EHR and IT services will likely contribute positively to Allscripts future performance. Because of this and their Q3 earnings, they have increased their non-GAAP revenue for the year to be in the range of $1.455 to $1.46 billion versus a prior range of approximately $1.44 to $1.45 billion. MDRX management slightly adjusted their operating income from $303 to $307 million. They estimate their net income to be in the range of $175 to $179 million, equating to a new EPS range of $0.91 to $0.93 per diluted share. Since their 3Q bookings performance did not reflect any international bookings, they expect their domestic bookings in the 4Q to be up substantially. Furthermore, they anticipate 90% of the balance with South Australian Public Health System to close in the 4Q, contributing to their estimate of 17% to 18% bookings growth for the year.

-Deven Gould, Health Care Sector Head
-Jorge Perez, Junior Health Care Analyst